[Treatment of osteoarticular infections with clindamycin in adults].
The main characteristics of clindamycin are adequate for treatment of osteoarticular infections (OAI): good bone diffusion, broad spectrum of antibacterial activity and oral use.


METHODS
A number of 61 patients was included in an observational retrospective study of efficacy and tolerance.


RESULTS
Prosthetic infections accounted for 50.8% of the cases and chronic osteitis for 36.1%. The causative micro-organisms were Staphylococci (72.2%) and Streptococci (15.3%); 86.5% of these strains were susceptible to erythromycin, 9.6% were erythromycin resistant and susceptible to lincomycin. Clindamycin was associated with either ofloxacine, rifampicin, or teicoplanin in 88.5% and the average course duration was 101 days. A surgical procedure was performed in 84% of cases. Complete cure was obtained in 91.1% at 18 months of follow up. Only one cutaneous rash and one Clostridium difficile-associated diarrhea occurred. The other adverse effects were gastrointestinal in 36%, cutaneous in 6.6%, and hematological in 1.6%, but did not lead to discontinuation of therapy.


CONCLUSIONS
Clindamycin can be used in OAI in association with or as an alternative to rifampicin, fluoroquinolones, or glycopeptides according to microbiological data.
El Samad
Y
Y
Service de maladies infectieuses et tropicales, hôpital Nord, CHU d'Amiens, place Victor-Pauchet, Amiens cedex, France. elsamad.youssef@chu-amiens.fr
Havet
E
E
Bentayeb
H
H
Olory
B
B
Canarelli
B
B
Lardanchet
J-F
JF
Douadi
Y
Y
Rousseau
F
F
Lescure
F-X
FX
Mertl
P
P
Eb
F
F
Schmit
J-L
JL
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology*; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D010000:Osteitis / Q000188:drug therapy* / Q000209:etiology; D019919:Prosthesis Implantation / Q000009:adverse effects; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology; D013514:Surgical Procedures, Operative / Q000009:adverse effects; D017334:Teicoplanin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D017334:Teicoplanin; D015242:Ofloxacin; D012293:Rifampin